Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Phase Ib, Study, to Determine Safety of Oral AL3810 in Patients With Locally Advanced or Metastatic Gastric, Hepatocellular or Nasopharyngeal Carcinoma

Next Previous
Trial Profile

An Open-label Phase Ib, Study, to Determine Safety of Oral AL3810 in Patients With Locally Advanced or Metastatic Gastric, Hepatocellular or Nasopharyngeal Carcinoma

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2018

At a glance

  • Drugs Lucitanib (Primary)
  • Indications Adenocarcinoma; Carcinoma; Gastric cancer; Liver cancer; Nasopharyngeal cancer
  • Focus Adverse reactions
  • Sponsors Haihe Biopharma; ShangHai HaiHe Pharmaceutical

    • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 28 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top